Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MilanaPharm
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
Surescripts maintained a monopoly on electronic prescription routing and eligibility markets through exclusive contracts with pharmacies and PBMs, complaint alleges.
LifeScan blood glucose monitoring system approved; firms form health alliance; and other briefs